<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938392</url>
  </required_header>
  <id_info>
    <org_study_id>112662</org_study_id>
    <nct_id>NCT00938392</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly</brief_title>
  <official_title>Immunogenicity &amp; Safety Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Estonia: State Agency of Medicines</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate immunogenicity between different formulations of
      GSK Biologicals' investigational vaccine GSK2186877A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Serum Haemagglutination-Inhibition (HI) Antibody Titers Against the 3 Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are presented as Geometric Mean Titers. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive Against the 3 Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for the 3 Vaccine Strains</measure>
    <time_frame>At Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for the 3 Vaccine Strains</measure>
    <time_frame>At Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for the 3 Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms and Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local symptoms assessed include ecchymosis, pain, redness and swelling. General symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, muscle aches, shivering and fever [oral temperature greater than or equal to 38 degrees Celsius (°C)]. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter. Grade 3 fever: oral temperature greater than or equal to 39°C. Related: general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local and General Symptoms</measure>
    <time_frame>During the 7-day post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local symptoms assessed include ecchymosis, pain, redness and swelling. General symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, muscle aches, shivering and fever. Duration is expressed as median number of days the specific symptom was experienced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 21-day post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Adverse Events of Specific Interest (AESI)</measure>
    <time_frame>During the 21-day post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>AESIs for safety monitoring included autoimmune diseases and other immune mediated inflammatory disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (up to Day 21)</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">726</enrollment>
  <condition>Influenza Infection</condition>
  <arm_group>
    <arm_group_label>FluNG Aged Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FluNG Fresh Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK investigational FluNG vaccine GSK2186877A, aged lot</intervention_name>
    <description>Single dose, intramuscular injection</description>
    <arm_group_label>FluNG Aged Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK investigational FluNG vaccine GSK2186877A, fresh lot</intervention_name>
    <description>Single dose, intramuscular injection</description>
    <arm_group_label>FluNG Fresh Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study. Specific attention
             should be given to the compliance potential of subjects with suspected or known drug
             or alcohol abuse.

          -  A man or woman 65 years of age or older at the time of vaccination.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             evaluation before entering into the study.

        Exclusion Criteria:

          -  Any confirmed or suspected influenza illness within the last 6 months.

          -  Previous vaccination against influenza with any seasonal vaccine since December 2008.

          -  Planned administration of an influenza vaccine other than the study vaccines during
             the entire study period.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use
             during the study period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines)
             or 4 weeks (for live vaccines) prior to enrolment in this study. Planned
             administration of a vaccine not foreseen by the study protocol up to Visit 2.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the dose of study vaccine or planned administration during the study
             period.

          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants
             or other immune-modifying drugs within six months prior to the vaccine dose. For
             corticosteroids, this will mean prednisone &gt;= 0.5 mg/kg/day, or equivalent. Inhaled
             and topical steroids are allowed.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine(s) including egg and chicken protein, included history of
             hypersensitivity to a previous dose of influenza vaccine.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.

          -  Acute disease and/or fever at the time of enrolment.

               -  Fever is defined as temperature &gt;= 37.5°C on oral setting.

               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
                  infection) without fever may be enrolled at the discretion of the investigator.

          -  Any medical conditions in which intramuscular injections are contraindicated.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>811 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>814 66</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>841 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Velky Biel</city>
        <zip>900 24</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>June 7, 2012</lastchanged_date>
  <firstreceived_date>July 9, 2009</firstreceived_date>
  <firstreceived_results_date>April 19, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza infection</keyword>
  <keyword>GSK Bio's influenza vaccine GSK2186877A</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects enrolled in the study did not receive any vaccination, and as such are not accounted for as started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FluNG Aged Group</title>
          <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
        </group>
        <group group_id="P2">
          <title>FluNG Fresh Group</title>
          <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="362"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FluNG Aged Group</title>
          <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
        </group>
        <group group_id="B2">
          <title>FluNG Fresh Group</title>
          <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="362"/>
                <measurement group_id="B2" value="362"/>
                <measurement group_id="B3" value="724"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73.3" spread="6.09"/>
                <measurement group_id="B2" value="73.5" spread="6.36"/>
                <measurement group_id="B3" value="73.4" spread="6.22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="239"/>
                <measurement group_id="B2" value="243"/>
                <measurement group_id="B3" value="482"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="123"/>
                <measurement group_id="B2" value="119"/>
                <measurement group_id="B3" value="242"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Haemagglutination-Inhibition (HI) Antibody Titers Against the 3 Vaccine Strains</title>
        <description>Titers are presented as Geometric Mean Titers. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom data concerning immunogenicity outcome variable measures were available for the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="357"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Haemagglutination-Inhibition (HI) Antibody Titers Against the 3 Vaccine Strains</title>
            <description>Titers are presented as Geometric Mean Titers. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Brisbane [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.1" lower_limit="12.7" upper_limit="15.8"/>
                  <measurement group_id="O2" value="13.4" lower_limit="12.1" upper_limit="14.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane [Day 21] (N= 357; 354)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108.4" lower_limit="95.8" upper_limit="122.6"/>
                  <measurement group_id="O2" value="108.7" lower_limit="95.1" upper_limit="124.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.5" lower_limit="16.1" upper_limit="21.3"/>
                  <measurement group_id="O2" value="19.1" lower_limit="16.7" upper_limit="21.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay [Day 21] (N= 357; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="291.5" lower_limit="251.9" upper_limit="337.4"/>
                  <measurement group_id="O2" value="282.7" lower_limit="244.6" upper_limit="326.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.2" lower_limit="59.3" upper_limit="78.4"/>
                  <measurement group_id="O2" value="62.3" lower_limit="54.8" upper_limit="70.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane [Day 21] (N= 357; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="537.9" lower_limit="483.6" upper_limit="598.3"/>
                  <measurement group_id="O2" value="534.2" lower_limit="483.5" upper_limit="590.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive Against the 3 Vaccine Strains</title>
        <description>A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom data concerning immunogenicity outcome variable measures were available for the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="357"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seropositive Against the 3 Vaccine Strains</title>
            <description>A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="220"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane [Day 21] (N= 357; 354)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="353"/>
                  <measurement group_id="O2" value="349"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="236"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay [Day 21] (N= 357; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="353"/>
                  <measurement group_id="O2" value="353"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="326"/>
                  <measurement group_id="O2" value="335"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane [Day 21] (N= 357; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="357"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for the 3 Vaccine Strains</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
        <time_frame>At Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom data concerning immunogenicity outcome variable measures were available for the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="356"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for the 3 Vaccine Strains</title>
            <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane (N= 356; 354)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="228"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="292"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="247"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for the 3 Vaccine Strains</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
        <time_frame>At Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom data concerning immunogenicity outcome variable measures were available for the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="356"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion Factor for the 3 Vaccine Strains</title>
            <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.</description>
            <units>Fold Increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Brisbane (N= 356; 354)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.7" lower_limit="6.6" upper_limit="8.9"/>
                  <measurement group_id="O2" value="8.1" lower_limit="6.9" upper_limit="9.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.8" lower_limit="13.4" upper_limit="18.6"/>
                  <measurement group_id="O2" value="14.8" lower_limit="12.7" upper_limit="17.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.9" lower_limit="6.8" upper_limit="9.3"/>
                  <measurement group_id="O2" value="8.6" lower_limit="7.4" upper_limit="9.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for the 3 Vaccine Strains</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom data concerning immunogenicity outcome variable measures were available for the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="357"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroprotected for the 3 Vaccine Strains</title>
            <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane [Day 21] (N= 357; 354)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="308"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120"/>
                  <measurement group_id="O2" value="131"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay [Day 21] (N= 357; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="338"/>
                  <measurement group_id="O2" value="337"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane [Day 0] (N= 356; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="261"/>
                  <measurement group_id="O2" value="260"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane [Day 21] (N= 357; 355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="357"/>
                  <measurement group_id="O2" value="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms and Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Local symptoms assessed include ecchymosis, pain, redness and swelling. General symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, muscle aches, shivering and fever [oral temperature greater than or equal to 38 degrees Celsius (°C)]. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter. Grade 3 fever: oral temperature greater than or equal to 39°C. Related: general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 7-day post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort including all vaccinated subjects with their symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="360"/>
                  <measurement group_id="O2" value="360"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms and Any, Grade 3 and Related Solicited General Symptoms</title>
            <description>Local symptoms assessed include ecchymosis, pain, redness and swelling. General symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, muscle aches, shivering and fever [oral temperature greater than or equal to 38 degrees Celsius (°C)]. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter. Grade 3 fever: oral temperature greater than or equal to 39°C. Related: general symptom assessed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="190"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local and General Symptoms</title>
        <description>Local symptoms assessed include ecchymosis, pain, redness and swelling. General symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, muscle aches, shivering and fever. Duration is expressed as median number of days the specific symptom was experienced.</description>
        <time_frame>During the 7-day post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort, on those subjects reporting the specific symptom only.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="190"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Solicited Local and General Symptoms</title>
            <description>Local symptoms assessed include ecchymosis, pain, redness and swelling. General symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, muscle aches, shivering and fever. Duration is expressed as median number of days the specific symptom was experienced.</description>
            <units>Days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Ecchymosis (N= 8; 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="6.0"/>
                  <measurement group_id="O2" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain (N= 180; 190)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness (N= 99; 106)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling (N= 45; 69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (N= 49; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (N= 86; 98)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal symptoms (N= 28; 29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (N= 66; 82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle aches (N= 60; 62)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering (N= 27; 26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                  <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (N= 4; 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 21-day post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort including all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="362"/>
                  <measurement group_id="O2" value="362"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Adverse Events of Specific Interest (AESI)</title>
        <description>AESIs for safety monitoring included autoimmune diseases and other immune mediated inflammatory disorders.</description>
        <time_frame>During the 21-day post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort including all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="362"/>
                  <measurement group_id="O2" value="362"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Adverse Events of Specific Interest (AESI)</title>
            <description>AESIs for safety monitoring included autoimmune diseases and other immune mediated inflammatory disorders.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the entire study period (up to Day 21)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort including all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Aged Group</title>
            <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
          <group group_id="O2">
            <title>FluNG Fresh Group</title>
            <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="362"/>
                  <measurement group_id="O2" value="362"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events were reported during the entire study (up to Day 21). Other Frequent (non-serious) Adverse Events were reported during a 7-day follow-up period after vaccination.</time_frame>
      <desc>Systematically assessed Other Frequent (non-serious) adverse events were reported for subjects with a completed symptom sheet only.</desc>
      <group_list>
        <group group_id="E1">
          <title>FluNG Aged Group</title>
          <description>Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).</description>
        </group>
        <group group_id="E2">
          <title>FluNG Fresh Group</title>
          <description>Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
